Trials / Completed
CompletedNCT03193047
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Esperion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bempedoic acid 180mg | Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy |
| OTHER | placebo | Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy |
| DRUG | evolocumab | Monthly PCSK9i (evolocumab) background therapy |
Timeline
- Start date
- 2017-04-07
- Primary completion
- 2018-01-29
- Completion
- 2018-02-19
- First posted
- 2017-06-20
- Last updated
- 2020-04-03
- Results posted
- 2020-04-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03193047. Inclusion in this directory is not an endorsement.